Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Details)

v3.22.4
Stockholders' Equity (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Stockholders' Equity (Details) [Line Items]      
Authorized to issue and sale of stock 17,000,000 700,000  
Common stock, shares authorized 12,000,000    
Common stock, par value (in Dollars per share) $ 0.001 $ 0.001  
Preferred stock, shares authorized 5,000,000 5,000,000  
Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001  
Preferred stock, shares outstanding  
Amount of ATM availability. (in Dollars) $ 200,000 $ 2,900,000  
Incurred professional fees (in Dollars)   $ 21,300  
Exercisable term 5 years    
Exercise price per share (in Dollars per share) $ 21.6    
Shares of common stock purchase 21,600 51,000  
Stock options term 10 years    
Awardee over a period 4 years    
Warrants to purchase common stock expired and cancelled 67,900    
Description of granted stock options   the Company granted stock options to employees to purchase 0.2 million shares of the Company’s common stock, including certain time and performance-based inducement awards, with grant date prices that ranged between $10.20 to $41.40 per share. The stock options have terms of ten years and are subject to vesting based on continuous service of the awardee over periods ranging from three to four years. The stock options have an aggregate grant date fair value of $5.8 million.  
Description of pursuant agreement   Pursuant to such agreement, the Company granted Dr. Sarret (1) a time-based inducement nonqualified stock option and (2) a performance-based inducement nonqualified stock option to purchase approximately 0.1 million shares of common stock. The options have an exercise price of $40.50  and the time-based grant will vest as to 25% of the shares on the one-year anniversary of the grant date, May 3, 2021, with the remaining shares subject to the option vesting in 36 equal monthly installments. The time-based inducement award has an aggregate grant date fair value of $2.2 million. As of December 31, 2021, Dr. Sarret satisfied a portion of the performance conditions and 21.6 thousand shares of the 43.3 thousand shares possible under the performance-based award vested. The performance-based award had a fair value of $0.1 million.  
Closing market price percentage 85.00%    
Issued shares of under ESPP 5,600 589  
Employee compensation deferrals (in Dollars) $ 25,000 $ 16,800  
Future issuance of shares under ESPP 10,500    
Warrant [Member]      
Stockholders' Equity (Details) [Line Items]      
Authorized to issue and sale of stock   1,700  
Shares of common stock purchase   48,400  
Warrants to purchase common stock expired and cancelled   106,000  
Cash proceeds (in Dollars)   $ 2,100,000  
Warrants purchase 9,600    
Purchase of warrants   2,000  
Common stock exercise price (in Dollars per share)   $ 41.4  
Vesting period, description   1.7 thousand of these warrants were valued using the Black-Scholes option pricing model and the corresponding expense will be recognized over the service period of three years. 0.3 thousand of these warrants were performance based. During the year ended December 31, 2021, the performance criteria were met and the warrants were valued and expensed at the time the performance conditions were met. The warrants have terms that range from two to three years with vesting over a one-year period.  
At-the-Market Offering [Member]      
Stockholders' Equity (Details) [Line Items]      
Authorized to issue and sale of stock 23,400 55,300  
Amount of ATM availability. (in Dollars) $ 5,000,000    
Underwritten Public Offerings [Member]      
Stockholders' Equity (Details) [Line Items]      
Authorized to issue and sale of stock   700,000  
Incurred professional fees (in Dollars)   $ 1,200,000  
Net of commissions (in Dollars)   $ 13,800,000  
Stock Option [Member]      
Stockholders' Equity (Details) [Line Items]      
Shares of common stock purchase   42,100 500,000
Options to purchase common stock 19,400    
Weighted average exercise price granted (in Dollars per share) $ 10.42    
Aggregate grant fair value (in Dollars) $ 200,000    
Cash proceeds (in Dollars)   $ 1,200,000  
Stock Option [Member] | 2011 plan [Member]      
Stockholders' Equity (Details) [Line Items]      
Remaining options to be issued 200,000